Publications by authors named "Leber Brian"

Claim this Profile
H
High-content imaging of primary chronic lymphocytic leukemia cells predicts patient cohorts with distinct cellular drug responses.
Mark X Li, Glauber C Brito, Jarkko Ylanko, Alla Buzina, Brian Leber

iScience· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world experience and outcomes of decitabine/cedazuridine or azacitidine for the treatment of myelodysplastic syndrome/chronic myelomonocytic leukemia.
Brittany Salter, Sarah Ge, Alejandro Garcia-Horton, Tobias Berg, Brian Leber

Leuk Lymphoma· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of expanding allogeneic stem cell transplantation on survival in acute myeloid leukemia: a population-based study.
Brittany Salter, Alejandro Garcia-Horton, Irwin Walker, Brian Leber, Kylie Lepic

Blood Cancer J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies.
Michael R Savona, Olatoyosi Odenike, Gail J Roboz, Harshad Amin, Amy E DeZern, Brian Leber

Br J Haematol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world validation study of the LSC17 score for risk prediction in patients with newly diagnosed acute myeloid leukemia.
Tracy Murphy, Boyang Zhang, Tong Zhang, Ian King, Jose-Mario Capo-Chichi, Brian Leber

Haematologica· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Cardiovascular Events in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.
Nazanin Aghel, Vincent Wang, Darryl Leong, Michelle Lui, Livia Fu, Brian Leber

JACC Adv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic Stem Cell Transplantation: The Relevance of Conditioning Regime Intensity for Myelodysplastic Syndromes (MDS).
Tobias Berg, Brittany Salter, Michael Radford, He Tian Tony Chen, Brian Leber

Curr Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.
Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, Karen W L Yee, Amer M Zeidan, Brian Leber

Future Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia.
Brian Leber, Marcia T Ruiz, Hany Elgendy, Filippa Pettersson, Thomas Prebet

Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"Discrepant low von Willebrand factor activity results on the ACL TOP analyzer are frequent in unselected patients with myeloproliferative neoplasms and show no correlation with high-molecular-weight multimer loss or bleeding phenotype": comment from Al Sharif et al.
Mohammed Abdullah Al Sharif, Brian Harnett, Subia Tasneem, Brian Leber, Christopher Hillis

J Thromb Haemost· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Economic Burden of Acute Myeloid Leukemia in Canada.
Jean Lachaine, Catherine Beauchemin, Fatéma Dodat, Yunghan Au, William K Evans, Brian Leber

Acta Haematol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement in quality of life in MDS patients who become transfusion independent after treatment.
Bo A Wan, Shabbir M H Alibhai, Lisa Chodirker, Lee Mozessohn, Michelle Geddes, Brian Leber

Leuk Lymphoma· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Mixed Donor Chimerism is a Strong Negative Prognostic Indicator in Allogeneic Stem Cell Transplant for AML and MDS.
Michael Radford, Alejandro Garcia-Horton, Rohail Badami, Elaine Jin, Nida Usmani, Brian Leber

Transplant Cell Ther· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Allogeneic Stem Cell Transplant in Patients with Relapsed/Refractory Hodgkin Lymphoma.
Shiliang Ge, Kylie Lepic, Ravi Bhindi, Tobias Berg, Dina Khalaf, Brian Leber

Curr Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The successful management of acute promyelocytic leukemia during pregnancy: a case report.
Brittany Salter, James Michael Radford, Tobias Berg, Brian Leber

Leuk Lymphoma· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
Keith W Pratz, Brian A Jonas, Vinod Pullarkat, Michael J Thirman, Jacqueline S Garcia, Brian Leber

Am J Hematol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial.
Arnon P Kater, Önder Arslan, Fatih Demirkan, Yair Herishanu, Burhan Ferhanoglu, Brian Leber

Lancet Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of cells of leukemic stem cell origin with non-canonical regenerative properties.
Cameron G Hollands, Allison L Boyd, Xueli Zhao, Jennifer C Reid, Charisa Henly, Brian Leber

Cell Rep Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms.
Tracy Murphy, Jacqueline M Mason, Brian Leber, Mark R Bray, Steven M Chan

Leukemia· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Combined results from two randomized controlled feasibility studies.
Rena Buckstein, Jeannie Callum, Anca Prica, David Bowen, Richard A Wells, Brian Leber

Am J Hematol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Results of a pilot randomized trial RBC-ENHANCE.
Rena Buckstein, Jeannie Callum, Anca Prica, David Bowen, Richard A Wells, Brian Leber

Transfusion· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Guillermo Garcia-Manero, James McCloskey, Elizabeth A Griffiths, Karen W L Yee, Amer M Zeidan, Brian Leber

Lancet Haematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
Maria Agustina Perusini, Igor Novitzky-Basso, Eshetu G Atenafu, Donna Forrest, Isabelle Bence-Bruckler, Brian Leber

Br J Haematol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy.
Fatima M Khadadah, Sonia Cerquozzi, Harold J Olney, Christina Fraga, Jill Dudebout, Brian Leber

Leuk Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leukemic progenitor compartment serves as a prognostic measure of cancer stemness in patients with acute myeloid leukemia.
Allison L Boyd, Justin Lu, Cameron G Hollands, Lili Alsostovar, Shiva Murali, Brian Leber

Cell Rep Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis